Company Filing History:
Years Active: 2009
Title: Mark Dixon: Innovator in Radiopharmaceuticals
Introduction
Mark Dixon is a notable inventor based in Southampton, GB. He has made significant contributions to the field of radiopharmaceuticals, particularly in the development of peptide-chelate conjugates. His work is essential for advancing diagnostic imaging techniques, especially in the context of colorectal cancer.
Latest Patents
Mark Dixon holds a patent for a peptide-chelate conjugate with affinity for the ST receptor. This innovative conjugate features a tetradentate chelate that can be labeled with a radiometal, resulting in a metal complex. The radiopharmaceutical composition derived from this complex is designed for diagnostic imaging of colorectal cancer. Additionally, the invention includes a kit for the preparation of the radiopharmaceutical preparation.
Career Highlights
Mark Dixon is associated with GE Healthcare Limited, where he applies his expertise in the development of medical technologies. His work has the potential to improve patient outcomes through enhanced diagnostic capabilities.
Collaborations
Mark has collaborated with notable colleagues, including Alan Cuthbertson and Marivi Mendizabal, to further his research and development efforts in the field of radiopharmaceuticals.
Conclusion
Mark Dixon's contributions to the field of radiopharmaceuticals, particularly through his innovative patent, highlight his role as a key inventor in advancing medical diagnostics. His work continues to pave the way for improved healthcare solutions.